Tirzepatide Side Effects: What the Research Shows
The short version
Tirzepatide side effects most frequently involve the digestive system — nausea, vomiting, diarrhoea, and constipation — especially during the early weeks of each dose increase. These are by far the most common reason people stop taking the medication. The FDA prescribing information also carries a boxed warning about thyroid tumours observed in rodent studies (not confirmed in humans), and clinical trial data show a statistically significant increase in gallbladder and biliary conditions. Hair thinning, lean-mass loss alongside fat loss, and weight regain after stopping the medication are additional considerations documented in the literature. The trial record behind each of these is cited below. For what patients and the research community report firsthand about side effects, see Tirzepatide effects.
Most common tirzepatide side effects — the trial record
Tirzepatide side effects across the SURPASS and SURMOUNT phase 3 programmes were overwhelmingly gastrointestinal in nature. Nausea, vomiting, diarrhoea, constipation, and decreased appetite were the most frequently reported adverse events in all major trials [1][2][3][4]. These effects are dose-related and emerge predominantly during dose escalation, generally attenuating with continued exposure.
A FAERS pharmacovigilance analysis of tirzepatide reports from May 2022 to Q2 2024 found nausea (27.7%) and diarrhoea (12.8%) were the most frequently reported gastrointestinal adverse events, with eructation (burping) and impaired gastric emptying carrying the highest disproportionality signals. Median time to onset of gastrointestinal events was 16 days, with most events occurring within three months [14].
A systematic review and meta-analysis of 13 randomised controlled trials in people with obesity without diabetes found tirzepatide was associated with a 2.94-fold higher overall gastrointestinal adverse-event risk versus placebo (RR 2.94, 95% CI 2.61–3.32), larger than the 1.68-fold increase with semaglutide [13]. These events were mostly mild to moderate but were the dominant driver of treatment discontinuations [15].
A retrospective FAERS analysis of 65,974 tirzepatide reports from 2022 to Q1 2025 additionally identified incorrect dose administration as the most frequently reported adverse event, increasing from 1,248 reports in 2022 to 9,800 in 2024, underscoring the importance of correct titration and injection technique [15].
Gallbladder, biliary disease, and pancreatitis signals
A meta-analysis of nine randomised controlled trials (9,871 participants) examining two specific safety signals found tirzepatide was not associated with a statistically significant increase in pancreatitis (RR 1.46, 95% CI 0.59–3.61), but was associated with a significantly increased composite risk of gallbladder or biliary disease (RR 1.97, 95% CI 1.14–3.42) versus controls [6]. No individual component — cholelithiasis, cholecystitis, or biliary disease — reached statistical significance on its own.
A separate meta-analysis of 12 trials (12,351 patients) reported a comparable gallbladder/biliary disease signal (RR 1.52, 95% CI 1.17–1.98) and a statistically significant cholelithiasis risk (RR 1.67, 95% CI 1.14–2.44) [16]. A class-level analysis of 21 randomised trials encompassing 99,599 patients found GLP-1 receptor agonists as a class increased gallbladder disorders by approximately 26% versus controls [17]. Rapid weight loss is a known precipitant of gallstone formation, which is consistent with the mechanism.
For pancreatitis specifically: a propensity-matched retrospective cohort of 258,238 patients with type 2 diabetes or obesity and a history of acute pancreatitis found tirzepatide users had the lowest five-year recurrent pancreatitis rate (6.2%), significantly lower than semaglutide users (11.7%) [18]. The signal is therefore monitored on the label but not confirmed as an elevated trial-level risk.
People taking tirzepatide who experience severe or persistent abdominal pain should seek medical evaluation.
Thyroid C-cell and MEN-2 boxed warning
The FDA prescribing information for tirzepatide carries a boxed warning regarding the risk of thyroid C-cell (medullary) tumours, based on rodent carcinogenicity studies in which structurally related incretin-class compounds caused dose- and duration-dependent thyroid C-cell tumours [7]. Whether this translates to humans is not established. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). A state-of-the-art safety review lists medullary thyroid carcinoma among the rare, theoretical class associations rather than demonstrated human risks [27].
Human epidemiological data on GLP-1 receptor agonists and thyroid cancer have not shown a consistent causal signal in observational studies, but the label-level contraindication is in place pending clearer evidence.
Lean-mass loss, hair loss, and weight regain after discontinuation
Beyond gastrointestinal and biliary effects, several additional tirzepatide side effects have been documented in the research literature.
Lean-mass loss: A SURMOUNT-1 DXA substudy found approximately 25% of the weight lost with tirzepatide was lean mass, with approximately 75% fat mass, proportions consistent across most subgroup analyses [19]. A systematic review of 35 randomised trials of incretin therapies found the median proportion of total weight loss attributable to muscle-related indices was 28.3% (IQR 15.9–39.9%) [20], and a narrative review described the rapid lean-mass loss as comparable to a decade or more of ageing and recommended resistance exercise training as an adjunct [21]. The clinical significance of this lean-mass change on physical function is still being defined.
Hair loss — telogen effluvium: Reversible diffuse hair shedding, attributed to telogen effluvium triggered by the physiological stress of rapid weight loss, has been documented in case-based reports and pharmacovigilance data [26]. Clinical trial data recorded hair loss in approximately 4–5% of participants versus 1% in placebo groups. It is typically self-limiting once weight stabilises.
Weight regain after discontinuation: A systematic review and meta-analysis found mean weight regain of approximately 9.69 kg in the semaglutide/tirzepatide group after stopping treatment, proportional to the initial weight loss [22]. SURMOUNT-4, a phase 3 randomised withdrawal study, demonstrated that participants switched to placebo regained a mean 14.0% of body weight from week 36 to week 88, while those continuing tirzepatide lost an additional 5.5% [23]. A post hoc analysis showed greater weight regain tracked with proportionally larger worsening of waist circumference, blood pressure, cholesterol, and HbA1c [24]. These data frame tirzepatide as requiring continuous therapy to maintain benefit.
Incorrect administration: A FAERS disproportionality analysis identified a strong signal for incorrect dose administration — one of the most reported events in the safety database — highlighting the importance of device education and titration guidance [15].
Perioperative aspiration risk and oral contraceptive interaction
Two additional label-directed cautions follow from tirzepatide's mechanism of delaying gastric emptying.
First, the long approximately five-day half-life and ongoing gastric-motility slowing create a theoretical risk of retained gastric contents under sedation or general anaesthesia. Documented aspiration is rare, but reviewers propose prolonged fasting, point-of-care gastric ultrasound, or prokinetic agents around procedures requiring anaesthesia [25].
Second, the FDA prescribing information advises that the effectiveness of oral hormonal contraceptives may be reduced during the period of greatest gastric-emptying delay — around each new dose and dose increase — because delayed gastric transit affects oral drug absorption. A non-oral or barrier contraceptive method is suggested by the label during that window [7][25].
For the full referenced list of sources underlying the safety discussion on this page, see Tirzepatide references.